Possibilities of using melatonin in gynecology
| Autor: | Н. В. Яроцкая, Е. В. Занько |
|---|---|
| Jazyk: | English<br />Russian<br />Ukrainian |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Репродуктивная эндокринология, Iss 34, Pp 96-101 (2017) |
| Druh dokumentu: | article |
| ISSN: | 2309-4117 2411-1295 |
| DOI: | 10.18370/2309-4117.2017.34.96-101 |
| Popis: | For the modern gynecologist, the problem of human aging acquires a special urgency – the tasks of preserving the reproductive potential of a woman, alleviating the symptoms of perimenopause come to the fore. Clinical manifestations of climacteric syndrome are very diverse and polysymptomatic and can vary from the presence of several symptoms to the development of the entire symptom complex. In the article the modern strategies of conducting women during menopausal transition and postmenopause are considered: hormone replacement therapy as the main method of correction and prevention of climacteric disorders, as well as auxiliary methods – phytoestrogens, anticonvulsants, antidepressants, agents acting on the autonomic nervous system, multivitamin complexes, plant extracts that are used more or less successfully in clinical practice. Melatonin preparations, analogues of one of the main endogenous adaptogens, are of particular interest in this series. This review describes the main effects of melatonin, its place in the complex treatment of the proliferative processes of the reproductive system, in particular, in the treatment of premenstrual syndrome, dysphoria, correction of sleep disorders in the perimenopause, its special role in the maturation of the follicle and ovulation. Melatonin is a universal natural adaptogen with a sleep effect, which is recommended by the National Consensus on the management of patients in menopause as a preparation of additional non-hormonal therapy. In the treatment of climacteric syndrome, it can be used at a dose of 1.5 mg 30 minutes before sleep for three months. It can be recommended as a monotherapy in the mild course of menopause and the prevalence of sleep disorders. If symptoms are more pronounced, melatonin should be combined with hormone replacement therapy. Synthetic analogue of melatonin is represented in Ukraine by drug Vita-Melatonin produced by PJSC “Kiev Vitamin Plant”. The drug allows to perform the task of increasing the effectiveness of therapy for various gynecological diseases. Not being selectively tropic to the reproductive system, melatonin promotes adaptation, improvement of the general condition and well-being of women in the climacteric period. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|